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Aims The AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK) trial investigated
whether ACE-inhibition reduces small abdominal aortic aneurysms (AAA) growth rate, independent of blood pressure
(BP) lowering.
Methods
and results
A three-arm, multi-centre, single-blind, and randomized controlled trial (ISRCTN51383267) was conducted in 14 hos-
pitals in England. Subjects aged ≥55 years with AAA diameter 3.0–5.4 cm were randomized 1:1:1 to receive perindo-
pril arginine 10 mg, or amlodipine 5 mg, or placebo and followed 3–6 monthly over 2 years. The primary outcome was
aneurysm growth rate (based on external antero-posterior ultrasound measurements in the longitudinal plane), deter-
mined by multi-level modelling to provide maximum likelihood estimates. Two hundred and twenty-four subjects were
randomized (2011–2013) to placebo (n ¼ 79), perindopril (n ¼ 73), or amlodipine (n ¼ 72). Mean (SD) changes in
mid-trial systolic BP (12 months) were 0.5 (14.3) mmHg, P ¼ 0.78 compared with baseline, 29.5 (13.1) mmHg
(P, 0.001), and26.7 (12.0) mmHg (P, 0.001), respectively. No significant differences in the modelled annual growth
rates were apparent [1.68 mm (SE 0.2), 1.77 mm (0.2), and 1.81 mm (0.2), respectively]. The estimated difference in
annual growth between the perindopril and placebo groups was 0.08 mm (CI 20.50, 0.65). Similar numbers of
AAAs in each group reached 5.5 cm diameter and/or underwent elective surgery: 11 receiving placebo, 10 perindopril,
and 11 amlodipine.
Conclusion Small AAA growth rates were lower than anticipated, but there was no significant impact of perindopril compared with
placebo or placebo and amlodipine, combined despite more effective BP lowering.
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Introduction
Each year in England and Wales 4000 deaths are attributed to ab-
dominal aortic aneurysm (AAA) rupture.1 There is a high mortality
associated with rupture (70–80%)2 and a much smaller but signifi-
cant mortality from elective aneurysm repair (1.3–4.7%).3,4
However, four randomized trials have shown that for small, slow
growing asymptomatic AAAs between 3.0 and 5.4 cm in diameter
surveillance is safe.5 Therefore, patients with small AAAs are gener-
ally enrolled on a surveillance programme, with repair considered
once the AAA diameter reaches 5.5 cm in size.6 After the compel-
ling results of the aneurysm screening trials,7,8 the National Health
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Service Abdominal Aortic Aneurysm Screening Programme
(NAAASP) was introduced in 2009 in the UK, with similar pro-
grammes in Sweden and elsewhere. Consequently, many smaller
AAAs are now being detected early. The majority (80%) of screen-
detected AAAs are small, with diameters of 3.0–4.4 cm1. If AAA
growth rates can be attenuated or halted in this expanding cohort
of patients, there is an opportunity to reduce the number of patients
at risk of AAA repair and rupture.
Animal studies have suggested a potential role of the renin–
angiotensin system (RAS) in AAA formation and growth.9 – 11
A case–control study on a group of over 15 000 patients with an
AAA, reported that patients who had previously received an
angiotensin-converting enzyme inhibitor (ACE-I) but not other anti-
hypertensive agents were 20% less likely to present with ruptured
aneurysm.12 Similarly, the Chichester small AAA surveillance study
suggested an association between angiotensin receptor blocker
(ARB) prescription and reduced AAA progression.13 Conversely,
post hoc analysis from both the UK Small Aneurysm Trial14 and
the PHAST trial15 failed to show that ACE-I slow aneurysm growth.
Given the, albeit inconsistent, observational evidence that RAS-
blockade might restrict AAA progression or lead to a decrease in
the risk of rupture, the AARDVARK (Aortic Aneurysmal Regression
of Dilation: Value of ACE-Inhibition on RisK) trial was designed.
The primary objective of this trial was to investigate whether an
ACE-I, perindopril, would reduce the growth rate of small AAAs
compared with placebo, independent of blood pressure (BP) reduc-
tion, assessed by including a third comparator arm in which BP was
lowered by amlodipine.
Methods
The study was approved by the Fulham Research Ethical Committee
(NRES 10/H0711/80) and was registered with the International Stand-
ard Randomized Controlled Trial Number registry (ISRCTN51383267).
The full protocol is available on the NIHR HTA website.16
Study design
This study was a randomized, single-blind, multicentre, and placebo-
controlled trial. Patients were randomized into one of three parallel
arms, receiving placebo, or perindopril (10 mg arginine salt), or amlodi-
pine (5 mg) daily. The doses of perindopril and amlodipine used were
estimated to have similar effects on BP thereby allowing an evaluation
of whether any benefits of perindopril on AAA growth observed
were independent of BP reduction.17 –19
Trial participants
Men or women, aged at least 55 years, with AAA 3.0–5.4 cm in diam-
eter by internal (inner anterior wall to the inner posterior (ITI) wall, or
intima to intima) or external (from the outer anterior to the outer pos-
terior (OTO) wall or adventitia to adventitia) measurement according
to ultrasonography and a systolic BP, 150 mmHg who consented to
participation in the trial were recruited.
Patients were excluded if they were already required to take an
ACE-I, ARB, or a calcium channel blocker – with the exception of
5 mg amlodipine, had known renal artery stenosis (.50%), had a serum
creatinine of .180 mmol/L, were unable to give informed consent,
were too frail to travel for 3–6 monthly surveillance, were reported
to have any clinically significant medical condition (including reduced
life expectancy of ,2 years), were unable or unwilling to comply with
study requirements, were participating in another trial of a product or
device within the previous 30 days, or had a known intolerance to peri-
ndopril or amlodipine.
Recruitment
Participants were recruited from 14 sites across England and six patient
identification centers that referred potential participants to the asso-
ciated research site for trial recruitment.
The clinical registries and the NAAASP databases at sites were used
to identify patients with small AAA. These patients were then pre-
screened against trial inclusion and exclusion criteria and given partici-
pant information. Reasons for ineligibility or non-participation were
recorded.
Trial eligibility was assessed at screening visits at which demographic
information, past medical history, and current medication history was
recorded. The most recent AAA ultrasound measurements were re-
viewed and written informed consent was obtained. Thereafter BP re-
cordings and blood samples for creatinine and electrolytes were taken.
Where the systolic BP of patients was ≥150 mmHg at screening, and
s/he was otherwise eligible for inclusion in the trial, sites were asked to
arrange for the patient to receive indapamide SR 1.5 mg daily or amlo-
dipine 5 mg, if the patient was not already taking a calcium channel
blocker: Their BP measurements were repeated after 6 weeks and if
the systolic BP fell to ,150 mmHg, patients were eligible to proceed
to randomization. For recruited patients who were not receiving a sta-
tin, sites requested the patients’ General Practitioner to prescribe one
as per current guidelines.20
Randomization and masking
Randomization was carried out through a web-based system using a
1:1:1 ratio among the three randomized groups, stratified by centre
and into one of two ranges of baseline aneurysm size: 3.0–4.5 and
4.51–5.40 cm. Randomization codes were generated using randomly
permutated blocks of varying sizes (Stata Corporation, TX, USA) by
an independent statistician. The trial was classified as single blind since
the three tablets prescribed were not identical in appearance. Drugs
were dispensed in identical opaque bottles and while technically pa-
tients could have investigated the composition of their prescribed trial
drug, neither patients, ultrasonographers nor site investigators were
aware of which tablets had been prescribed to each patient.
Drugs were deblistered into bottles labelled A, B, or C and dispensed
at each visit. For the initial 2 weeks following randomization, patients
were asked to take half doses of their trial drug, in line with standard
clinical practice for the initiation of perindopril, and therefore applied
to all three randomized groups.
Where in-trial cough was persistent and intolerable, patients stopped
the trial drug for 2 weeks and if the cough resolved they were changed
to losartan (100 mg/day). If the cough continued (and hence deemed
unrelated to trial drug), the drug was restarted. All patients who were
switched to losartan continued in the trial and were followed up on an
intention to treat basis.
Compliance with the trial drug was evaluated using tablet counts by a
designated member of the pharmacist. Compliance (expressed as a per-
centage) was calculated as a ratio of tablets taken (based on pill counts
of tablets returned) divided by the number of tablets that should have
been consumed.
Trial procedures
Each patient had a maximum of nine planned study visits. At the baseline
visit, patients underwent a review of informed consent, demographic in-
formation, medical history, and current medical therapies. In addition,
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aortic ultrasonography and BP measurement were carried out as per
study protocol. Screening blood results were checked before random-
ization and dispensing of study medication took place.
Following this baseline visit, patients attended every 3 or 6 months
(with the 3 months and yearly visits being mandatory), as well as ap-
pointments mandated on clinical grounds, for a total of 2 years. At
each visit, BP, aneurysm diameter, any adverse events (AE), and serious
adverse events (SAE) were recorded.
Three sitting BPs were measured using a validated semi-automated
device: Omron 705CP-II machines (Omron Healthcare, Hoofddorp,
the Netherlands) or the BP Plus device (Uscom, Sydney, Australia) after
at least 10 min rest. The mean of the last two readings were used in ana-
lyses. Smoking was not permitted in the 30 min before BP measurement.
At each visit, four antero-posterior AAA measurements of maximum
diameter were collected by qualified vascular scientists or technicians
accredited in aortic ultrasonography using a detailed protocol: ITI and
OTO measurements in the transverse and longitudinal planes.
Blood creatinine and electrolyte levels were collected at screening,
3, 12, and 24 months (in keeping with recommended clinical practice
for the management of hypertension with an ACE-I), reviewed by the
study team and the Data Safety Monitoring Committee (DSMC). Medi-
cation was discontinued if the serum creatinine rose .30% above base-
line. Patients with lesser increases in creatinine were monitored, advised
by the results of more frequent blood tests as clinically indicated.
Data were entered onto purpose built corresponding electronic
forms with built-in validation rules to identify data entry errors in real
time and provide a full audit trail of data entry and changes.
Quality assurance
The baseline images of all patients were assessed for quality by the trial
Senior Clinical Vascular Ultrasonographer (SCVU). Thereafter, ultra-
sound images taken at subsequent 3 or 6 monthly visits were reviewed
for a random sample of 10 patients per site (or all participants for sites
with ,10 patients). Based on these assessments, observers received
onsite remedial training sessions as required.
Quality assurance events were organized to ensure consistency be-
tween and within observers, given the use of up to four observers at
any one site. Based on outcomes of these events, OTO diameters
measured from longitudinal images were used for evaluation as the pri-
mary outcome as these were the most repeatable: The mean differ-
ence for this measurement between trial observer and trial SCVU
was 0.035+ 4 mm.
Outcome measures
The primary outcome of the trial was aneurysm growth rate over
2 years, estimated from the sequential AAA diameter measurements
(external diameter measured in the longitudinal plane).
Secondary outcome measures include: changes in BP; the composite
outcome of time taken for the aneurysm to reach the 5.5 cm diameter
threshold, referral for elective surgery or AAA rupture; drug intoler-
ance; and drug compliance.
Adverse event reporting, safety, and data
monitoring
This trial was conducted in accordance with Medical Research Council
Guidelines for Good Clinical Practice and the Medicines for Human Use
(Clinical Trials) Regulations 2004.
Safety was assessed during the trial by local recording of AEs, SAEs.
Independent in-trial monitoring took place at all sites according to spe-
cific protocols.
Statistical analyses
Based on the inclusion of 225 patients with a baseline AAA of
,5.5 cm diameter, and estimated growth rates (based on UKSAT of
2.6 mm/year),6 the trial was powered to 90% at the 5% level to detect
a 38% (1 mm) difference in growth rate associated with the ACE-I com-
pared with placebo. On the assumption that the effects on aneurysm
progression are specific to ACE-Is rather than other anti-hypertensive
drugs, the trial was powered to detect a smaller difference in growth
rate (,20%) by comparing the ACE-I group with the other two groups
combined. These calculations allowed for 10% attrition, defined as a par-
ticipant having attended fewer than two study visits, hence a direct meas-
ure of growth rate was not possible. The placebo-corrected AAA growth
rate in the amlodipine group could be used for evaluation of the extent to
which any ACE-I effect on growth rate was attributable to BP reduction.
Patients were censored at the time of the AAA reaching 5.5 cm in diam-
eter (in any of the measurements), referral for surgery, elective aneurysm
repair, aneurysm rupture, death, or at the end of the study.
The statistical analyses followed a pre-specified plan. Maximum AAA
diameter growth from baseline to Month 24 was analysed using linear-
mixed models (multi-level modelling) where repeated measurements
were nested within subjects. A random-coefficient model with treat-
ment group and time interaction as fixed effects and a random slope
of time was fitted to allow patients to differ in their rate of diameter
growth and test the difference in growth rate between treatment
groups.
For secondary analyses, differences between groups were tested
using paired t-tests and differences at different time points between
groups were analysed using linear regression adjusted for baseline. Log-
transformation was used for non-normally distributed variables.
The composite secondary endpoint (time taken to reach 5.5 cm, or
being referred to/having surgery, or AAA rupture) was analysed using
Kaplan–Meier plots for descriptive analysis and the log-rank test was
used to assess differences between treatments.
All treatment evaluations were performed on the principle of ‘inten-
tion to treat’ unless otherwise specified. All statistical tests were two
tailed at the 5% significance level.
Results
Within the recruitment period, 2139 patients were assessed for eli-
gibility. Of the 1912 non-recruited patients, 317 declined, and 1595
were ineligible most commonly due to their current medication
(40% were taking an ACE-I, 10% an ARB, and 11% the highest
dose of any calcium channel blocker).
Between 16 December 2011 and 19 April 2013, 227 patients
were randomized to the trial. Three patients were excluded after
randomization because they did not meet trial entry criteria and
were removed from the ITT dataset on the advice of the DSMC.
The baseline characteristics for all 224 correctly randomized pa-
tients are shown in Table 1. The full CONSORT diagram is shown in
Figure 1. In all, 10 patients withdrew from the study or died before
completing at least two study visits—an attrition rate of 4%. The
mean duration of follow-up of the placebo, perindopril, and amlodi-
pine groups was 617, 623, and 584 days, respectively.
Throughout the trial, mean systolic and diastolic BP levels re-
mained largely unchanged among those allocated to placebo but
fell in the amlodipine group, and more so in the perindopril group
(Figure 2). For example, mean changes in systolic BP midway through
the trial (12 months) were 0.5 mmHg (standard deviation 14.3, P ¼
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0.78 compared with baseline), 29.5 mmHg (13.1, P, 0.001), and
26.7 mmHg (12.0, P, 0.001) in the placebo, perindopril, and
amlodipine groups, respectively. Mean changes in diastolic BP at
12 months were 20.2 mmHg (standard deviation 7.3, P ¼ 0.78
compared with baseline), 25.8 mmHg (8.1, P, 0.001), and
24.7 mmHg (7.5, P, 0.001).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Baseline characteristics of randomized patients
Placebo Perindopril Amlodipine
N 79 73 72
Age (years) 70.7 (7.5) 71.6 (6.9) 71.5 (6.7)
Male, n (%) 74 (94%) 71 (97%) 66 (92%)
Caucasian, n (%) 79 (100%) 73 (100%) 71 (99%)
Systolic blood pressure (mmHg) 131.7 (12.2) 130.9 (11.5) 131.9 (13.0)
Diastolic blood pressure (mmHg) 77.9 (7.6) 76.7 (8.0) 78.0 (7.0)
Use of statins, n (%) 48 (61%) 53 (73%) 45 (63%)
AAA external diameter longitudinal (cm) 4.06 (0.67) 4.05 (0.65) 4.03 (0.69)
Current smokers, n (%) 17 (22%) 21 (29%) 18 (25%)
Pack years for current smokers 32.9 (28.0) 33.1 (24.0) 29.3 (17.3)
Past smokers, n (%) 56 (72%) 41 (57%) 44 (63%)
Pack years past smokers 42.2 (45.5) 42 (33.8) 40.5 (36.8)
Height (cm) 174.4 (8.5) 175.9 (8.3) 173.7 (8.7)
Weight (kg) 84.3 (16.1) 84.3 (16.6) 81.2 (13.8)
Diabetes, n (%) 8 (10.1%) 2 (2.7%) 6 (8.3%)
Anti-platelet therapy, n (%) 28 (35.4%) 37 (50.6%) 33 (45.8%)
Data are mean (SD) unless otherwise stated.
Figure 1 AARDVARK CONSORT diagram.
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The estimated average annual AAA diameter growth was
1.68 mm (standard error 0.2) in the placebo group, 1.77 mm (0.2)
in the perindopril group, and 1.81 mm (0.2) in the amlodipine group
(Table 2). The differences in the average growth rates were not signifi-
cant between perindopril and placebo (P ¼ 0.78). The estimated dif-
ference in annual growth between the perindopril and placebo
groups was 0.08 mm (confidence intervals 20.50, 0.65). The differ-
ence in average growth rate between those allocated to perindopril
and amlodipine groups was not significant (P ¼ 0.89) nor was the dif-
ference between those allocated to perindopril, compared with those
allocated to placebo and amlodipine combined (P ¼ 0.92). Maximum
likelihood estimates for longitudinal external AAA diameter growth
adjusted for baseline age–sex, statin use, and current smoking status
showed very similar results. A sensitivity analysis, excluding the few
patients with diabetes, did not affect the overall finding with an esti-
mated difference in annual growth rate between the perindopril and
placebo groups of20.01 mm with 95% confidence intervals of20.6,
0.6 mm. A further sensitivity analysis, including the three post-
randomization exclusions, also showed no difference in annual
growth rate between any of the groups. Also including the site in
the model as random effect or fixed effect did not change the results.
No significant differences were found among the three rando-
mized groups (11, 10, and 11 in the placebo, perindopril, and amlo-
dipine groups, respectively) in terms of the number of patients
who reached the composite secondary endpoint of time taken to
reach 5.5 cm or being referred to/having surgery or AAA rupture
(Figure 3). There were no AAA ruptures.
Mean compliance combining all three groups was 81–88% for
each 3-month period evaluated. There was no significant difference
in compliance between groups at any time point.
Both active drugs were generally well tolerated with similar num-
bers of patients discontinuing therapy for AEs among the three
groups (8, 13, and 14 among those randomized to the placebo, peri-
ndopril, and amlodipine groups, respectively). Six patients withdrew
from the trial due to AEs attributed to study medications (two at-
tributed to perindopril, four to amlodipine). Four patients (three
randomized to perindopril and one to amlodipine) switched to lo-
sartan due to cough.
Small differences in the numbers of SAEs were reported among
the three trial groups (16, 19, and 12 events in the placebo, perindo-
pril, and amlodipine groups, respectively) but none of the recorded
SAEs were deemed to be related to the trial medications by the
principal investigators at the sites where the events occurred.
There were non-significant minor differences in the median ser-
um creatinine concentration recorded at each stage of the trial in
those allocated to placebo and amlodipine. However, a 6% non-
significant increase in serum creatinine was apparent at 3 months
in those allocated to perindopril and similarly elevated levels were
maintained thereafter. No patients were withdrawn from the trial
due to concerns about renal function.
Figure 2 Mean systolic and diastolic BP over the duration of the trial by randomized group.
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Table 2 Maximum likelihood estimates from linear mixed model for (a) longitudinal external abdominal aortic
aneurysms diameter growth (mm) and (b) mean abdominal aortic aneurysms diameter estimates (mm) at 24 months
Fixed parameters Estimate Standard error P
(a)
Average baseline diameter for the control group 40.74 0.73
Average growth rate (mm/year) for the control group 1.68 0.20
Difference in average baseline diameter
Perindopril vs. placebo 20.08 1.06 0.94
Amlodipine vs. placebo 20.21 1.06 0.85
Difference in average growth rate (mm/year):
Perindopril vs. Placebo 0.08 0.29 0.78
Amlodipine vs. Placebo 0.12 0.30 0.68
Test for overall three group growth rate differencea 0.91
Random parameters
SD of individual intercepts 6.46 0.31
SD of individual slopes 1.49 0.11
Correlation between intercepts and slopes 4.55 0.75
SD of residual errors 1.36 0.03
(b)
Treatment 24 month estimate [95% CI]
Placebo 44.11 [42.26, 45.96]
Perindopril 44.19 [42.25, 46.13]
Amlodipine 44.15 [42.20, 46.10]
aFor treatment by time interaction (x2 test (2 d.f.)).
Figure 3 Kaplan–Meier estimates of proportion of patients reaching 5.5 cm in abdominal aortic aneurysms diameter during the course of the
trial or having/being referred for abdominal aortic aneurysms surgery. Ten randomized patients are not included since they were only seen at
baseline. One further patient was not included in the Kaplan–Meier graph as at baseline had one of the four diameter measurements ≥5.5. There
is an apparent disparity with numbers of patients attending their 24-month visit largely due to this visit occurring before 720 days.
C.D. Bicknell et al.3218
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Discussion
In this randomized trial the ACE-I, perindopril did not affect the
overall growth rate of small AAAs during 2 years of follow-up com-
pared with amlodipine or placebo. The estimated difference in an-
nual growth rate between perindopril and placebo remained
similar after adjustment for known factors that affect aneurysm
growth rate and after sensitivity analysis excluding patients with dia-
betes which is associated with reduced AAA growth rate.6 Add-
itionally, in this trial there was no difference in the number of trial
patients whose AAA grew to a maximum diameter of 5.5 cm or
more and/or were referred for or received elective repair. The
AARDVARK trial was designed, to study AAA growth, as a pilot trial
for a larger trial of the impact of ACE-Is on AAA-related adverse
clinical events including rupture and surgical repair.
Mean BP levels in the perindopril and amlodipine arms showed sig-
nificant reductions between baseline and 24 months, but there were
no differences in growth rates between those in the placebo group and
those in the two actively treated groups. Although there is a known
association between raised BP and aneurysm prevalence (particularly
high diastolic readings),21 evidence to support increased aneurysm
growth rates in hypertensive patients is lacking. This trial suggests
that at least among those with baseline systolic BP,150 mmHg, a sys-
tolic/diastolic BP reduction using perindopril, compared with placebo,
of on average 8/5 mmHg throughout the trial (Figure 2A and B) does
not have a significant impact on AAA growth rate.
This trial was designed to evaluate any BP independent effect in
AAA growth rate of perindopril. Hence, the doses of perindopril
and amlodipine were selected to achieve similar reductions in BP.
Therefore, any BP-independent effects of ACE-I on AAA growth rates
could be evaluated. However, although both treatments were effective
in lowering BP, there were surprisingly greater reductions in systolic
and diastolic BP in those receiving perindopril despite similar with-
drawal and compliance rates in each group. This greater reduction in
BP by an ACE-I in an elderly population of patients with AAA deserves
further study. One possible explanation could be that patients had a
high rate of unrecognized renal artery stenosis and ACE-Is are particu-
larly effective in terms of BP lowering in this context.
The overall findings of the AARDVARK trial are at odds with sev-
eral laboratory and animal-based studies9 –11 including the findings
that angiotensinogen and the angiotensin type 1 receptors (but not
angiotensin type 2 receptors) are increased by a factor of 2 in the
walls of AAAs compared with control tissue.11 Similarly in hypercho-
lesterolaemic mice, infusion of angiotensin II leads to dissection of the
aorta, generating supra-renal aortic aneurysms, the formation of
which can be prevented with use of an ACE-I.9 In addition, perindopril
has also been shown to inhibit aortic degeneration and AAA forma-
tion in other AAA animal models induced by elastase and calcium
chloride.10 Similarly, some13 but not all14,15 large observational stud-
ies have generated findings which are inconsistent with these AARD-
VARK trial findings, in suggesting that RAS-blockade may protect
against the growth of AAAs. It is not clear why these inconsistencies
arise but may at least in part be related to confounding due to the re-
duced use of ACE-Is by smokers in the observational analyses.
The AAA growth rates observed in this trial were smaller than
reported in previous studies6,7,22 – 24 where growth rates ranged
between 1.6 and 2.6 mm per year in aneurysms with a mean baseline
diameter between 3.4 and 4.3 cm. This may be secondary to the
more aggressive control of cardiovascular risk factors, which is
more routinely found in current clinical practice than was the case
at the time of these previous studies and to the pre-requisite of a
reasonably ‘controlled’ baseline systolic BP level before entry to
the AARDVARK trial. The average baseline BPs in studies that
have primarily measured small AAA growth rate were certainly
higher than those of the participants in the AARDVARK trial
(131.5/77.5 mmHg at baseline) ranging from 143 to 157 mmHg (sys-
tolic) and 81–91 mmHg (diastolic).6,7,22,23 Limitations of the
AARDVARK trial include the potential for being under-powered
to detect a small but important effect on AAA growth rate. Sample
size calculations were based on an estimated annual growth rate in
AAA diameter of 2.6 mm (SD 1.8) and a treatment effect of 38%
(1 mm) as reported in the UKSAT trial.6 Given the actual average
growth rate observed of 1.7 mm with an SD of 3.0, 190 patients
per group would have been required to detect a 1 mm difference
in annual growth with a power of 90%. Given the sample size (75
per group) this trial had 51% power to detect a 1 mm difference
in growth (between two groups) and 85% power to detect a differ-
ence of 1.5 mm (close to the annual growth rate). However, the es-
timated difference in annual growth between the perindopril and
placebo groups was 0.08 mm with confidence intervals of 20.50,
0.65. This statistically excludes a likely reduction of 1 mm per year
with perindopril administration. The potential for lack of generaliz-
ability of the results must be acknowledged, since this trial was per-
formed in a largely white male population, whose BP levels were
relatively well controlled. In addition, the results may not be applic-
able to patients with larger aneurysms, but since 80% of screen-
detected aneurysms have diameters of 3.0–4.4 cm1 it appears
unlikely that ACE-I would slow the growth of most screen-detected
aneurysms. Finally, there is a possibility that there may be an effect of
ACE-I administration that is only evident after 2 years.
Despite these limitations, this is a unique randomized controlled
trial investigating the effect of ACE-I on small aneurysm growth rates
followed up for 2 years. Although a small and expected increase in
creatinine levels was seen in the ACE-I group, trial withdrawals due
to study drug-related AEs were similar among the three groups and
compliance with therapy was excellent in all three treatment arms.
In conclusion, the AARDVARK trial, which is the first randomized
trial to report the effect of ACE-Is in this setting, found no evidence
that in patients with systolic BP of ,150 mmHg, the rate of growth
of small AAAs is slowed by the administration of the ACE-I perindopril
compared with placebo and that modest BP lowering did not beneficial-
ly impact on the growth of small AAAs. Consequently, although peri-
ndopril was well tolerated and safe in a population of patients with
AAA, the growing number of patients with small aneurysms found as
a result of increased monitoring and screening appear unlikely to benefit
from ACE-I administration in terms of the growth of their small AAAs.
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